Company intelligence / Profile preview

Innoventus

Suzhou, Jiangsu, Chinadnb.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has launched 13 products in the market, has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials, and 17 more molecules in early clinical stage. Recently, DOVBLERON® (taletrectinib adipate capsule) was approved by China's NMPA for treating ROS1-positive NSCLC.[5]

Therapeutic areas: OphthalmologyOncologyImmunologyCardiovascular
Modalities: Monoclonal antibodiessmall molecules
Industry: Biotech

Drug pipeline

1 asset

ML214

Pre-clinical

Indications: Cancer, Inflammation

Partnerships

Eli LillySanofiIncyteAdimabLG ChemMD Anderson Cancer Center

Beyond the preview

Go deeper on Innoventus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innoventus.

Explore the full profile